Night sweats
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Night sweats are episodes of drenching sleep-time sweating that affect up to 75% of people going through menopause and can signal several other hormonal or medical conditions.
What it is
Night sweats affect up to 75% of people during the menopausal transition, making them one of the most reported hormonal symptoms in Canadian primary care. Night sweats — also called sleep hyperhidrosis or nocturnal diaphoresis — are episodes of intense, drenching sweating during sleep that soak clothing or bedding and are not explained by an overheated room. They are the nocturnal form of hot flashes (vasomotor symptoms), but they can also arise from infections, malignancies, medications, and other endocrine disorders unrelated to menopause. Because the symptom is non-specific, clinicians typically work through a differential before attributing night sweats to hormonal change alone.
In Canada, night sweats are among the top reasons perimenopausal and postmenopausal patients consult a family physician or seek care through virtual platforms. The Society of Obstetricians and Gynaecologists of Canada (SOGC) addresses vasomotor symptoms — the category that includes both hot flashes and night sweats — in its menopause clinical practice guidelines, which were updated in 2021.
Causes and mechanism
The leading hormonal cause is declining estrogen during perimenopause and menopause, which narrows the thermoregulatory "neutral zone" in the hypothalamus. Small rises in core body temperature that would normally go unnoticed instead trigger a full heat-dissipation response: peripheral vasodilation, flushing, and profuse sweating. The episode typically lasts 1–5 minutes and may be followed by chills.
Non-menopausal causes are clinically important and include:
| Category | Examples |
|---|---|
| Hormonal / endocrine | Hyperthyroidism, pheochromocytoma, carcinoid tumors, androgen deprivation therapy |
| Infectious | HIV, tuberculosis, endocarditis, brucellosis |
| Malignant | Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia |
| Medications | Antidepressants (SSRIs/SNRIs), methadone, hypoglycemic agents, hormone therapy itself |
| Neurological / other | Obstructive sleep apnea, autonomic neuropathy, anxiety disorders |
Research published in PMC (2019) found that seasonal variation influences the pattern of night sweats, with peaks preceding hot flash peaks — suggesting the two symptoms share a mechanism but are not identical in timing.
Symptoms and diagnosis
A clinically significant night sweat is one that disrupts sleep or requires a change of clothing or bedding. Isolated mild warmth at night is not the same as true nocturnal diaphoresis. Associated features that raise concern for a non-menopausal cause include fever, unintentional weight loss, lymphadenopathy, or onset in a person who is not in the expected age range for perimenopause.
Workup in Canada typically begins with a detailed history and may include:
- TSH (thyroid-stimulating hormone) to rule out hyperthyroidism
- CBC and ESR/CRP if infection or malignancy is suspected
- FSH and estradiol if menopausal status is uncertain (LifeLabs and Dynacare both offer these panels)
- Fasting glucose if hypoglycemia is a concern
- HIV testing where clinically indicated
There is no single validated severity scale in routine Canadian clinical use, though the Menopause Rating Scale and the Hot Flash Related Daily Interference Scale are used in research settings.
Treatment options
Hormone therapy (HT) is the most effective treatment for vasomotor night sweats related to menopause. The SOGC and The Menopause Society both support HT as first-line therapy for healthy individuals under 60 or within 10 years of menopause onset, absent contraindications such as estrogen-receptor-positive breast cancer or active thromboembolic disease. In Canada, estradiol patches, gels, and oral formulations are available by prescription; most provincial drug benefit plans cover at least one formulation.
Non-hormonal prescription options include:
- Low-dose SSRIs or SNRIs (paroxetine, venlafaxine) — paroxetine 7.5 mg is the only non-hormonal agent with FDA approval specifically for vasomotor symptoms, though it is used off-label in Canada at various doses
- Gabapentin — evidence supports modest benefit, particularly for night-time symptoms
- Fezolinetant (Veozah) — a neurokinin 3 receptor antagonist approved by Health Canada in 2023 for moderate-to-severe vasomotor symptoms; it is the first non-hormonal, non-antidepressant option in this class available in Canada
Lifestyle measures with evidence of modest benefit include keeping the bedroom below 19°C, using moisture-wicking bedding, avoiding alcohol and spicy food within 2–3 hours of sleep, and not smoking. These are appropriate first steps for mild symptoms or as adjuncts to medication.
Cognitive behavioural therapy (CBT) has demonstrated statistically significant reductions in the bothersomeness of vasomotor symptoms in randomized trials, though it does not reduce the physiological frequency of sweating.
When to see a clinician in Canada
See a family physician or nurse practitioner promptly if night sweats are accompanied by fever, unexplained weight loss (more than 5% of body weight over 6 months), swollen lymph nodes, or if you are not in a typical perimenopausal age range. For menopause-related symptoms, a referral to a menopause specialist or gynecologist is appropriate when first-line options have failed. Virtual care platforms operating in Canada — including Maple, Felix, Cleo, Phoenix, and others — can provide initial assessment and prescriptions for many patients, though complex cases warrant in-person evaluation. The SOGC's menopause specialist directory can help locate a clinician with specific expertise.
Limitations and open questions
Research is still emerging on the long-term cardiovascular and cognitive implications of severe, untreated vasomotor symptoms. The relationship between night sweat frequency and sleep architecture disruption is not fully characterized. Health Canada has not yet issued specific guidance on compounded bioidentical hormone preparations for night sweats, and evidence for their safety and efficacy relative to regulated products remains limited. The optimal duration of non-hormonal agents like fezolinetant beyond 52 weeks has not been established. Racial and ethnic differences in vasomotor symptom burden — documented in U.S. cohort data showing longer duration in Black and Hispanic women — have not been studied in depth in Canadian populations.
FAQs
Are night sweats always caused by menopause?
No. While menopause is the most common hormonal cause — affecting up to 75% of people in the menopausal transition — night sweats can also result from infections such as HIV or tuberculosis, lymphomas, hyperthyroidism, certain medications including antidepressants, and obstructive sleep apnea. A clinician will typically rule out these other causes, especially if you have additional symptoms like fever or unexplained weight loss, before attributing night sweats to menopause alone.
How is a night sweat different from just being too warm in bed?
A clinically significant night sweat is one that drenches your clothing or bedding and disrupts sleep, regardless of room temperature. Feeling warm or mildly sweaty because of heavy blankets or a hot room is not the same as nocturnal diaphoresis. True night sweats often wake the person and may be followed by chills as the body overcorrects. If you are regularly changing your clothes or sheets due to sweating, that warrants a clinical assessment.
Is hormone therapy covered by provincial drug plans in Canada?
Coverage varies by province. Most provincial and territorial drug benefit plans — including Ontario's ODB, BC PharmaCare, and Quebec's RAMQ — cover at least one estrogen formulation and one progestogen, though the specific products on formulary differ. Patients may need to try a covered product before a non-formulary option is approved. Checking your provincial formulary or asking a pharmacist is the fastest way to confirm what is covered for your specific plan.
What non-hormonal prescription options are available in Canada for night sweats?
As of 2023, Health Canada has approved fezolinetant (brand name Veozah), a neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms including night sweats — the first in its class available in Canada. Low-dose SSRIs and SNRIs such as paroxetine and venlafaxine are also used off-label and have evidence supporting a 50–60% reduction in vasomotor symptom frequency. Gabapentin is another off-label option with particular benefit for nighttime symptoms. None of these are as effective as hormone therapy for most patients.
How long do menopausal night sweats typically last?
Duration varies considerably. U.S. cohort data from the SWAN study found that vasomotor symptoms persist for a median of about 7 years from onset, and for more than 10 years in some individuals. Symptoms that begin before the final menstrual period tend to last longer than those that start after. African American and Hispanic women have been shown to experience vasomotor symptoms for more years on average than white or Asian women, though Canadian-specific data on this variation are limited.